93-02-7-manufacture,factory,supplier from China

Oral version of simelglutide approved for marketing in China, clinical results show that it can effectively lower sugar and lose weight.On January 26, 2024, the official website of the State Drug Administration (SDA) showed that Simeglutide tablets developed by Novo Nordisk were approved for marketing for the treatment of type 2 diabetes. This is also the first oral GLP-1 receptor agonist approved for marketing in China.

1.The development trend of pharmaceutical intermediates industryThe development of fine chemicals is one of the solid foundations of China's construction of a manufacturing power, but also to achieve the national energy saving and emission reduction targets, the development of a low-carbon economy is an important path. Fine chemical industry production process is complex, the production of raw materials and products involving hazardous chemicals, safety and environmental risks are high.

2024 CW domestic exhibition programMarch 13-15, 2024 The 14th China International New Fertilizer Exhibition (FSHOW) National Convention and Exhibition Center (Shanghai)March 20-22, 2024 The 27th China International Food Additives and Ingredients Exhibition (FSHOW) National Convention and Exhibition Center (Shanghai)March 27-29, 2024 2024 The 14th China (Zhengzhou) Plastics Industry Expo? Zhengzhou International Convention & Exhibition CenterApril 09-11, 2024 The 3rd China (Jinan) New Chemical Materials & Fine Chemicals Exhibition Shandong International Convention & Exhibition Cente

Compound synthesis customization, drug intermediates synthesis Dr., to undertake all kinds of compound customization, route design, drug intermediates synthesis customization.

Dear Customers.We will attend the 21st World Pharmaceutical Ingredients Shanghai on June 19th - 21st.Welcome to discuss business with us and create business opportunities together!What's app: +8618663721413Greetings from Shandong Liteng Biotechnology Co., Ltd.